SPECTRUM PHARMACEUTICALS INC Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2022-05-12: Study NCT05378763; Company role Lead sponsor; Phase Phase 3; Status Suspended.
- 2021-05-20: Study NCT04570423; Company role Lead sponsor; Phase Phase 2; Status Recruiting.
- 2021-04-08: Study NCT04981704; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2021-01: Study NCT02847949; Company role Lead sponsor; Phase Phase 1; Status Withdrawn.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2022-05-12 | NCT05378763 A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations | Lead sponsor | Phase 3 | Suspended | NSCLC | 268 | 2028-12-25 |
| 2021-05-20 | NCT04570423 A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy | Lead sponsor | Phase 2 | Recruiting | Solid Tumors; Lymphoma | 40 | 2027-10 |
| 2021-04-08 | NCT04981704 A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants | Lead sponsor | Phase 1 | Completed | Healthy | 74 | 2021-08-17 |
| 2021-01 | NCT02847949 A Study of IGN002 for Refractory NHL | Lead sponsor | Phase 1 | Withdrawn | NHL | 0 | 2025-12 |
| 2020-06-23 | NCT04402008 Study of Poziotinib in Japanese Patients With NSCLC | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | NSCLC | 42 | 2023-02-15 |
| 2020-05-29 | NCT04436562 Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects | Lead sponsor | Phase 1 | Completed | Healthy | 8 | 2020-07-17 |
| 2020-03-11 | NCT04187898 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer | Lead sponsor | Phase 1 | Completed | Neutropenia; Breast Cancer | 59 | 2024-08-16 |
| 2019-12-23 | NCT04172597 A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies | Lead sponsor | Phase 2 | Terminated Results posted | Breast Cancer; Colorectal Cancer; Solid Tumor; Glioblastome Multiforme | 1 | 2022-03-29 |
| 2019-06-25 | NCT03804515 A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib | Lead sponsor | Phase 1 | Terminated | Solid Tumor | 2 | 2020-06-17 |
| 2018-10-11 | NCT03744715 A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib | Lead sponsor | Phase 2 | Terminated Results posted | NSCLC; Breast Cancer | 7 | 2023-03-03 |
| 2018-07-13 | NCT03429101 A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | Lead sponsor | Phase 1 | Terminated | Breast Cancer | 6 | 2019-04-17 |
| 2018-01-08 | NCT02994784 Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients | Collaborator Lead: Boston Medical Center | Phase 2 | Terminated Results posted | Amyloidosis; Systemic | 27 | 2022-07-01 |
| 2017-10-11 | NCT03318939 Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | Lead sponsor | Phase 2 | Terminated Results posted | NSCLC | 648 | 2023-04-03 |
| 2017-08-04 | NCT03224182 A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) | Lead sponsor | Phase 3 | Terminated Results posted | Bladder Cancer | 118 | 2019-09-26 |
| 2017-05-11 | NCT03135951 Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy | Lead sponsor | Phase 1 | Completed | Breast Cancer; Pharmacokinetics | 26 | 2018-05-18 |
| 2017-05-10 | NCT02953340 SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide | Lead sponsor | Phase 3 | Completed Results posted | Neutropenia; Breast Cancer | 237 | 2019-05-06 |
| 2017-05-10 | NCT02257242 Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma | Collaborator Lead: Brown University | Phase 1 | Completed Results posted | Lymphoma, Non-Hodgkin; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Small-Cell; Waldenstrom Macroglobulinemia; Lymphoma, B-Cell, Marginal Zone | 11 | 2020-11-18 |
| 2017-03-17 | NCT03066206 Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Terminated | EGFR Exon 20 Mutation; ERBB2 Gene Mutation; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7 | 93 | 2026-02-16 |
| 2017-01-31 | NCT02879643 Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy | Collaborator Lead: Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 | Completed Results posted | ALL, Childhood; Lymphoblastic Leukemia, Acute, Childhood; Lymphoblastic Leukemia, Acute | 29 | 2024-12-31 |
| 2016-11-23 | NCT02518750 Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | Collaborator Lead: St. Jude Children's Research Hospital | Phase 2 | Terminated Results posted | Acute Lymphoblastic Leukemia; Lymphoma, Non-Hodgkin's; Leukemia, T-Cell; Leukemia, B-Cell | 3 | 2018-03-11 |
| 2016-09 | NCT02909036 Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | Collaborator Lead: Memorial Sloan Kettering Cancer Center | Phase 1 | Active not recruiting | Multiple Myeloma; Amyloidosis | 46 | 2026-09 |
| 2016-05-01 | NCT02519270 Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects | Lead sponsor | Phase 1 | Terminated | Non-Hodgkin Lymphoma | 62 | 2018-05-04 |
| 2016-02-22 | NCT02659514 Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer | Lead sponsor | Phase 2 | Completed Results posted | Breast Cancer | 67 | 2020-03-11 |
| 2016-01-19 | NCT02643420 SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) | Lead sponsor | Phase 3 | Completed Results posted | Neutropenia; Breast Cancer | 406 | 2018-10-31 |
| 2016-01 | NCT02014545 Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer | Collaborator Lead: Wake Forest University Health Sciences | Phase 2 | Withdrawn | Brain Metastases; Non-small Cell Lung Cancer | 0 | 2017-11-29 |
| 2015-12 | NCT02532192 A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Collaborator Lead: M.D. Anderson Cancer Center | Phase 1 | Withdrawn | Lymphoma | 0 | |
| 2015-10-09 | NCT02563561 A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) | Lead sponsor | Phase 3 | Terminated Results posted | Bladder Cancer | 62 | 2017-03-10 |
| 2015-06-05 | NCT02337478 Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Collaborator Lead: Wake Forest University Health Sciences | Phase 2 | Terminated Results posted | Recurrent Adult Acute Myeloid Leukemia | 5 | 2017-09-04 |
| 2014-05-07 | NCT02137759 MRSI to Predict Response to RT/TMZ ± Belinostat in GBM | Collaborator Lead: Emory University | Phase 2 | Unknown | Glioblastoma Multiforme of Brain | 29 | 2024-08-15 |
| 2013-05 | NCT01741155 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) | Lead sponsor | Phase 2 | Terminated | Non Small Cell Lung Cancer (NSCLC) | 34 | 2015-07 |
| 2013-04 | NCT01773785 Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer | Lead sponsor | Phase 2 | Terminated | Biliary Cancer | 30 | 2015-09 |
| 2013-03-25 | NCT01724866 Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer | Lead sponsor | Phase 2 | Completed Results posted | Neutropenia | 148 | 2014-08-12 |
| 2013-03-12 | NCT01811368 Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | Collaborator Lead: Joseph Tuscano | Phase 2 | Unknown | Refractory Non Hodgkin Lymphoma; Relapsed Non Hodgkin Lymphoma | 20 | 2023-12 |
| 2013-03-05 | NCT01319981 Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Completed Results posted | Leukemia | 31 | 2020-11-11 |
| 2013-01 | NCT01490723 Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Completed Results posted | Leukemia; Lymphoma | 20 | 2019-04-24 |
| 2012-12-11 | NCT01662102 Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) | Lead sponsor | Phase 3 | Terminated Results posted | Follicular Lymphoma | 1 | 2013-03-05 |
| 2012-06-19 | NCT01587144 Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) | Lead sponsor | Phase 2 | Terminated | Glioblastoma Multiforme | 18 | 2013-04-15 |
| 2012-04-19 | NCT01510184 Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy | Lead sponsor | Phase 3 | Terminated Results posted | Diffuse Large B-cell Lymphoma; Follicle Center Lymphoma | 79 | 2014-10-23 |
| 2012-04 | NCT01560884 Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb | Lead sponsor | Phase 1 | Completed | Safety; Phosphate Binding Capacity | 32 | 2012-09 |
| 2012-03 | NCT01439347 A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL | Lead sponsor | Phase 3 | Terminated Results posted | Acute Lymphoblastic Leukemia (ALL) | 26 | 2015-11 |
| 2012-02 | NCT01497275 Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | Collaborator Lead: Duke University | Phase 2 | Terminated Results posted | Mantle-Cell Lymphoma | 5 | 2014-05 |
| 2012-01 | NCT01469221 Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) | Lead sponsor | Phase 3 | Terminated Results posted | Bladder Cancer | 47 | 2013-04 |
| 2011-11 | NCT01549886 Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma | Lead sponsor | Phase 2 | Terminated Results posted | Non-Hodgkin's Lymphoma | 5 | 2015-05 |
| 2011-11 | NCT01478542 OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine | Collaborator Lead: Universität des Saarlandes | Phase 3 | Completed | CD20+ Aggressive B-Cell Lymphoma | 1,152 | 2024-01-18 |
| 2011-08 | NCT01420679 Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients | Lead sponsor | Phase 3 | Terminated Results posted | Peripheral T-cell Lymphoma | 21 | 2017-12 |
| 2011-07-06 | NCT01336933 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | Collaborator Lead: University of Nebraska | Phase 2 | Completed Results posted | Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma | 34 | 2016-12-28 |
| 2011-07 | NCT01410565 Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer | Lead sponsor | Phase 3 | Terminated Results posted | Bladder Cancer | 66 | 2014-03 |
| 2010-12 | NCT01317927 A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies | Lead sponsor | Phase 1 | Completed | Solid Tumor; Hematological Malignancy | 27 | 2015-06 |
| 2010-11 | NCT01252693 International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer | Lead sponsor | Phase 2 | Completed | Prostate Cancer | 203 | 2015-05 |
| 2010-10 | NCT01234766 Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma | Collaborator Lead: Dartmouth-Hitchcock Medical Center | Phase 2 | Completed Results posted | Lymphoma, Follicular | 39 | 2021-04-01 |
| 2010-07 | NCT01129206 Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy | Collaborator Lead: Ohio State University Comprehensive Cancer Center | Phase 2 | Completed Results posted | Adenocarcinoma of the Esophagus; Adenocarcinomas of the Gastroesophageal Junction; Recurrent Esophageal Cancer; Squamous Cell Carcinoma of the Esophagus; Stage IV Esophageal Cancer | 6 | |
| 2009-09 | NCT00998946 Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | Lead sponsor | Phase 2 | Completed Results posted | Lymphoma, B-Cell | 29 | 2012-08 |
| 2009-02 | NCT00873119 Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary | Collaborator Lead: Valerio Therapeutics | Phase 2 | Completed Results posted | Carcinoma of Unknown Primary | 89 | 2012-12 |
| 2008-12-15 | NCT00865969 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma | Lead sponsor | Phase 2 | Completed Results posted | Peripheral T-cell Lymphoma | 129 | 2014-10-27 |
| 2008-12-04 | NCT00743184 Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH) | Lead sponsor | Phase 2 | Terminated | Benign Prostatic Hyperplasia (BPH); Lower Urinary Tract Symptoms (LUTS) | 28 | 2010-01-20 |
| 2008-11-10 | NCT00765973 Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | Lead sponsor | Phase 1 | Completed | Small Cell Lung Cancer; Ovarian Cancer; Solid Tumors | 14 | 2010-06-30 |
| 2008-09 | NCT01448928 Zevalin Post-marketing Surveillance in Japan | Lead sponsor | Observational | Completed | Non-Hodgkin's Lymphoma (NHL) | 400 | 2018-01-31 |
| 2008-04-03 | NCT00656786 Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash | Lead sponsor | Phase 1 | Completed | EGFR Inhibitor-associated Rash | 18 | 2009-12-30 |
| 2008-04 | NCT01207765 Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma | Collaborator Lead: Tufts Medical Center | Phase 2 | Terminated Results posted | Multiple Myeloma | 8 | 2013-06 |
| 2008-04 | NCT00112060 A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Non-Small-Cell Lung Carcinoma | 0 | 2011-09 |
| 2008-01 | NCT00613691 A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma | Lead sponsor | Phase 1 | Completed | Carcinoma | 36 | 2012-12 |
| 2008-01 | NCT00606502 Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment | Lead sponsor | Phase 2 | Completed Results posted | Non-small Cell Lung Cancer | 201 | 2010-06-24 |
| 2007-11 | NCT00558727 Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | Lead sponsor | Phase 1 | Terminated | Advanced Solid Tumors; Non-Hodgkin's Lymphoma | 12 | 2008-12 |
| 2007-11 | NCT00506142 Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma | Lead sponsor | Phase 2 | Completed Results posted | Metastatic Malignant Uveal Melanoma | 54 | 2014-12 |
| 2007-08 | NCT00598806 Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) | Lead sponsor | Phase 3 | Completed Results posted | Bladder Cancer | 812 | 2012-01 |
| 2007-05 | NCT00495079 Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | Lead sponsor | Phase 2 | Completed Results posted | Acute Lymphoblastic Leukemia (ALL) | 65 | 2010-08-08 |
| 2007-04 | NCT00461591 Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611) | Lead sponsor | Phase 3 | Completed Results posted | Bladder Cancer | 802 | 2012-01 |
| 2007-01-23 | NCT00427219 The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate | Lead sponsor | Phase 2 | Completed | Benign Prostatic Hypertrophy | 74 | 2008-02-27 |
| 2006-12 | NCT00878800 A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas | Collaborator Lead: Valerio Therapeutics | Phase 1, Phase 2 | Completed Results posted | Dose Escalation: Solid Tumors; MTD: Soft Tissue Sarcomas | 41 | 2012-10 |
| 2006-10 | NCT00384111 Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) | Lead sponsor | Phase 3 | Terminated Results posted | Follicular Lymphoma; Lymphoma, Follicular | 26 | 2008-11 |
| 2006-07 | NCT00364676 Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease | Lead sponsor | Phase 1 | Completed | Tumors; Hodgkins Disease; Non-Hodgkins Lymphoma | 67 | 2015-08 |
| 2006-06 | NCT00413075 Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | Collaborator Lead: Valerio Therapeutics | Phase 1 | Completed | Solid Tumor; Lymphoma | 121 | 2011-08 |
| 2006-05 | NCT00322218 Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma. | Lead sponsor | Phase 3 | Terminated Results posted | Lymphoma, Large Cell, Diffuse | 68 | 2008-12 |
| 2005-07 | NCT00141531 Phase II Trial of EOquin in High-risk Superficial Bladder Cancer | Lead sponsor | Phase 2 | Completed | Bladder Neoplasms | 53 | 2009-12 |
| 2005-07 | NCT00129558 A Study to Evaluate PT-523 in Patients With Refractory Leukemia | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Leukemia | 0 | 2011-09 |
| 2004-05 | NCT00184080 Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Collaborator Lead: University of Southern California | Phase 2 | Completed | Non-Hodgkin's Lymphoma | 7 | 2006-04 |
| 2004-04 | NCT00090090 Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | Lead sponsor | Phase 2 | Completed | Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 114 | 2006-10 |
| 2004-03 | NCT00088023 Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness | Lead sponsor | Phase 1 | Terminated | Neoplasms | 40 | 2005-12 |
| 2004-02 | NCT00083304 Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer | Lead sponsor | Phase 3 | Completed | Breast Cancer; Metastases | 368 | 2007-06 |
| 2002-11 | NCT00055887 Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer | Lead sponsor | Phase 3 | Withdrawn | Lung Cancer | 0 | |
| 2002-08 | NCT00052442 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Lymphoma | 72 | 2009-03 |
| 2000-02 | NCT00005887 Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases | Lead sponsor | Phase 3 | Completed | Metastatic Cancer | 2003-01 | |
| 1998-10 | NCT00004202 Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer | Lead sponsor | Phase 2 | Completed | Lung Cancer | 2003-01 |